The Global Neurodegeneration Proteomics Consortium (GNPC) published a series of papers unveiling unique plasma protein signatures across Alzheimer's, Parkinson's, frontotemporal dementia, and amyotrophic lateral sclerosis. Analyzing 35,000 biofluid samples encompassing approximately 250 million protein measurements, researchers delineated both shared and distinct pathways driving neurodegeneration and aging. These biomarkers offer promise for early detection and tailored therapeutics. Bill Gates noted the consortium as a prime example of global scientific collaboration advancing breakthrough diagnostics and antibody treatments for Alzheimer’s disease.